Pharmacist-in-charge at Tianjin Hospital | China
Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.
Professional Profiles
Scopus Profile | ORCID Profile
Education
Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.
Experience
With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.
Research Interest
Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.
Awards and Honors
Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.
Research Skills
Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.
Publication Top Notes
Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025
Conclusion
Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.
